November 2019—ChromaCode announced publication of a study by the Medical College of Wisconsin, Milwaukee, and Gundersen Medical Foundation, La Crosse, Wis., highlighting the performance and utility of the High-Definition PCR Tick-Borne Pathogen Panel RUO.
The multisite study (Buchan BW, et al. J Clin Microbiol. 2019;57[11]:e00513–e00519) tested a combination of clinical whole blood samples and simulated samples with ChromaCode’s TBP panel. Four hundred twenty-five clinical specimens and 93 simulated specimens were tested with TBP. For clinical samples, the TBP panel demonstrated a 100 percent positive percent agreement for the identification of Anaplasma phagocytophilum, Borrelia miyamotoi, Borrelia mayonii, and Rickettsia rickettsii and negative percent agreement greater than 99.8 percent for all nine TBP targets. For the simulated specimens, the TBP panel demonstrated a sensitivity and specificity of 100 percent and 99.9 percent, respectively.
ChromaCode, 442-244-4370